Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emerging Companies

How published research underpinned a cancer therapy awareness campaign

Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment - and wanted to better understand the disease and treatment challenges faced by both...

Research Partnership

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...

Research Partnership

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

Research Partnership

- PMLiVE

Shire offloads oncology unit to Servier for $2.4bn

The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...

Research Partnership

Celgene building

Celgene bulks up pipeline again with $2.1bn Prothena deal

Acquires candidates with potential in Alzheimer’s, ALS and dementia

- PMLiVE

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

The duo will start a series of clinical trials combining the multiple RTK inhibitor and Keytruda

Research conducted by Research Partnership published in leading medical journal

Findings from a study conducted by Research Partnership have recently been published in the ‘Supportive Care in Cancer’ journal

Research Partnership

EISAI

NICE reverses its rejection of Eisai’s Lenvima

The cost-effectiveness watchdog has now backed the thyroid cancer treatment

Roche Basel Switzerland

Roche to buy cancer data firm Flatiron for $1.9bn

Data provides a wealth of RWE opportunities

Lynch syndrome: a patient perspective

Blue Latitude Health intern Costantino Ciotti gives an insight into life with Lynch Syndrome, a genetic condition associated with colon cancer. Here he explores the patient’s perspective, including treatment options,...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links